WILLIAM PEACOCK to Pulmonary Embolism
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Pulmonary Embolism.
Connection Strength
4.402
-
Reducing the hospital burden associated with the treatment of pulmonary embolism. J Thromb Haemost. 2019 05; 17(5):720-736.
Score: 0.508
-
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016 11; 23(11):1280-1286.
Score: 0.429
-
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism? Clin Appl Thromb Hemost. 2017 Oct; 23(7):830-837.
Score: 0.422
-
Target-specific Oral Anticoagulants in the Emergency Department. J Emerg Med. 2016 Feb; 50(2):246-57.
Score: 0.402
-
Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule within an all-payer inpatient administrative claims database. BMJ Open. 2015 Oct 28; 5(10):e009251.
Score: 0.400
-
Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis. Eur Heart J. 2024 Aug 21; 45(32):2933-2950.
Score: 0.184
-
Prevalence of Pulmonary Embolism in Patients With Syncope. J Am Coll Cardiol. 2019 08 13; 74(6):744-754.
Score: 0.130
-
The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis. 2019 Jul; 48(1):149-157.
Score: 0.129
-
Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS One. 2017; 12(10):e0185022.
Score: 0.115
-
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 09; 33(9):1697-1703.
Score: 0.113
-
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul; 39(7):1426-1436.e2.
Score: 0.112
-
External validation of the multivariable 'In-hospital Mortality for PulmonAry embolism using Claims daTa' prediction rule in the Premier Hospital Database. Eur Heart J Qual Care Clin Outcomes. 2017 04 01; 3(2):157-159.
Score: 0.110
-
Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. BMC Pulm Med. 2017 Feb 13; 17(1):37.
Score: 0.109
-
External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. Intern Emerg Med. 2017 Aug; 12(5):613-619.
Score: 0.109
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.109
-
Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. J Thromb Thrombolysis. 2016 Nov; 42(4):513-9.
Score: 0.107
-
External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Serv Res. 2016 10 22; 16(1):610.
Score: 0.107
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.107
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.106
-
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Int J Cardiol. 2016 Nov 01; 222:846-849.
Score: 0.106
-
Outcomes related to variation in hospital pulmonary embolus observation stay utilization. Hosp Pract (1995). 2016 Aug; 44(3):133-7.
Score: 0.104
-
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. Clin Appl Thromb Hemost. 2017 Oct; 23(7):769-774.
Score: 0.104
-
Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. Thromb Res. 2016 May; 141:8-10.
Score: 0.102
-
External validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) multivariable prediction rule. Int J Clin Pract. 2016 Jan; 70(1):82-8.
Score: 0.100
-
D-dimer Levels in Acute, Medically Ill, Hospitalized Patients: A Large, Prospective, Multicenter Study in the United States. Clin Appl Thromb Hemost. 2025 Jan-Dec; 31:10760296251320406.
Score: 0.047
-
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Curr Med Res Opin. 2017 09; 33(9):1717-1723.
Score: 0.028